T Cell News and Research

Latest T Cell News and Research

The Methodist Hospital Research Institute awarded $11.5M NIH grant for research into methods of targeting cancer stem cells

The Methodist Hospital Research Institute was awarded an $11.5 million Center Grant by the National Institutes for Health (NIH) today to study the best way to attack deadly cancer stem cells to enhance treatments for breast cancer. Other members of the team include Baylor College of Medicine and the University of Texas Health Science Center at Houston.

19 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Highly fit multiple sclerosis patients perform significantly better on tests of cognitive function than similar less-fit patients, a new study shows.

18 Feb 2010

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics Inc. reported today its results for the quarter and year ended December 31, 2009. The company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.

18 Feb 2010

Single microRNA exhibits potential to forecast outcomes of MPM

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published online on February 16th, 2010, and are set to be published in the March 1st issue of the American Association for Cancer Research’s journal, Cancer Research.

18 Feb 2010

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

A signaling protein that is key in orchestrating the body's overall immune response has an important localized role in fighting bacterial infection and inflammation in the intestinal tract, according to a study by UC San Diego School of Medicine investigators, published in the journal Cell Host and Microbe.

18 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

18 Feb 2010

BrainStorm Cell Therapeutics secures funds for ALS clinical trials

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it has entered into agreements with three investors with each investing $500,000 for a total of investment of $1.5 million into BrainStorm.

18 Feb 2010

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.

18 Feb 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.

18 Feb 2010

New research units established for Japanese-German research collaboration

With its ten new Research Units, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is intensifying interdisciplinary and multiple-location collaboration among researchers pursuing specific scientific questions and new avenues of research.

17 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Research published in February's edition of the Journal of Thoracic Oncology investigates the utilization of surgery and the subsequent need for radiotherapy (RT) when treating stage I small cell lung cancer (SCLC). Traditionally, SCLC treatment regimes include chemotherapy and radiotherapy for limited stage disease; however, the study concludes that in selected patients with early stage disease a lobectomy (removal of lung) had an excellent overall survival without additional treatment.

17 Feb 2010

Researchers discover new strategy to overcome drug resistance in breast cancer

Combining tamoxifen, the world's most prescribed breast cancer agent, with a compound found in the flowering plant feverfew may prevent initial or future resistance to the drug, say researchers at Georgetown Lombardi Comprehensive Cancer Center.

17 Feb 2010

Directing gold nanoparticles into nucleus can kill cancer cells

Taking gold nanoparticles to the cancer cell and hitting them with a laser has been shown to be a promising tool in fighting cancer, but what about cancers that occur in places where a laser light can't reach? Scientists at the Georgia Institute of Technology have shown that by directing gold nanoparticles into the nuclei of cancer cells, they can not only prevent them from multiplying, but can kill them where they lurk. The research appeared as a communication in the February 10 edition of the Journal of the American Chemical Society.

17 Feb 2010

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).

17 Feb 2010

ACT's research on therapeutic cell types obtained from iPS cells featured in leading news media outlets

Advanced Cell Technology or “ACT” announced today that its research involving therapeutic cell types obtained from induced pluripotent stem (iPS) cells has been featured in several leading news media outlets: Scientific American, USA Today and Newsweek.

17 Feb 2010

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

Researchers at the Swedish medical university Karolinska Institutet have discovered a protein that is crucial in mediating the anti-inflammatory actions of nuclear lipid receptors. The findings, published in the research journal Genes & Development, link lipid metabolism and inflammation and open up new possibilities for developing treatments of metabolic diseases associated with inflammation, such as diabetes and atherosclerosis.

17 Feb 2010

UWM engineer creates software program that foresees outcome before stem cell divides

A software program created by an engineer at the University of Wisconsin-Milwaukee (UWM) can not only predict the types of specialized cells a stem cell will produce, but also foresee the outcome before the stem cell even divides.

17 Feb 2010

T Cell News and Research

Latest T Cell News and Research

The Methodist Hospital Research Institute awarded $11.5M NIH grant for research into methods of targeting cancer stem cells

Rituxan, intended for patients with CLL receives FDA approval

Highly fit MS patients perform better on tests of cognitive function than less-fit patients: Study

Antigenics announces fourth-quarter and full-year 2009 financial results

Single microRNA exhibits potential to forecast outcomes of MPM

Signaling protein has key role in fighting bacterial infection and inflammation in intestinal tract: Study

Viral infection can suppress immune response to secondary bacterial infection

FDA issues Complete Response Letter for Horizant in treatment of RLS

BrainStorm Cell Therapeutics secures funds for ALS clinical trials

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Genzyme announces fourth-quarter and full-year 2009 financial results

New research units established for Japanese-German research collaboration

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Researchers discover new strategy to overcome drug resistance in breast cancer

Directing gold nanoparticles into nucleus can kill cancer cells

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

ACT's research on therapeutic cell types obtained from iPS cells featured in leading news media outlets

Protein crucial in mediating anti-inflammatory actions of nuclear lipid receptors discovered

UWM engineer creates software program that foresees outcome before stem cell divides

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in